Literature DB >> 22083486

Micafungin concentrations in the plasma and burn eschar of severely burned patients.

Junichi Sasaki1, Satoshi Yamanouchi, Daisuke Kudo, Tomoyuki Endo, Ryosuke Nomura, Kiyotsugu Takuma, Shigeki Kushimoto, Yotaro Shinozawa, Satoshi Kishino, Shingo Hori, Naoki Aikawa.   

Abstract

Micafungin concentrations in plasma and burn eschar after daily intravenous infusion (1 h) of micafungin (200 to 300 mg) were investigated for six patients with severe burns. Micafungin treatment was initiated more than 72 h after the burn injuries. The peak and trough levels in the plasma after the initial administration and repeated administrations for more than 4 days were comparable with or slightly lower than the reported values for healthy volunteers. Micafungin concentrations in the plasma and burn eschar were between 3.6 and >1,000 times higher than the reported MIC(90)s of micafungin against clinically important Candida and Aspergillus species.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22083486      PMCID: PMC3264244          DOI: 10.1128/AAC.05381-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections.

Authors:  Kenji Tabata; Masataka Katashima; Akio Kawamura; Atsunori Kaibara; Yusuke Tanigawara
Journal:  Drug Metab Pharmacokinet       Date:  2006-08       Impact factor: 3.614

2.  Fluconazole pharmacokinetics in burn patients.

Authors:  B A Boucher; S R King; H L Wandschneider; W L Hickerson; S D Hanes; V L Herring; T W Canada; M M Hess
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 3.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Candidemia and invasive candidiasis: a review of the literature for the burns surgeon.

Authors:  Jennifer F Ha; Claire M Italiano; Christopher H Heath; Sophia Shih; Suzanne Rea; Fiona M Wood
Journal:  Burns       Date:  2010-04-14       Impact factor: 2.744

5.  Candida in burns: risk factors and outcomes.

Authors:  Edwina C Moore; Alexander A Padiglione; Jason Wasiak; Eldho Paul; Heather Cleland
Journal:  J Burn Care Res       Date:  2010 Mar-Apr       Impact factor: 1.845

Review 6.  Pharmacokinetics of antibiotics in burn patients.

Authors:  M J Weinbren
Journal:  J Antimicrob Chemother       Date:  1999-09       Impact factor: 5.790

7.  Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats.

Authors:  Toshiro Niwa; Yoshiko Yokota; Akira Tokunaga; Yasuhiro Yamato; Akira Kagayama; Tomoichi Fujiwara; Junko Hatakeyama; Masaharu Anezaki; Yuko Ohtsuka; Akira Takagi
Journal:  Biol Pharm Bull       Date:  2004-07       Impact factor: 2.233

Review 8.  Micafungin.

Authors:  Blair Jarvis; David P Figgitt; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics in patients with burns.

Authors:  U Jaehde; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

View more
  7 in total

1.  [Not Available].

Authors:  Jf Arnould; R Le Floch
Journal:  Ann Burns Fire Disasters       Date:  2015-03-31

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries.

Authors:  M J Asensio; M Sánchez; B Galván; E Herrero; L Cachafeiro; A Agrifoglio; E Perales; S Luque; A García-de-Lorenzo
Journal:  Intensive Care Med       Date:  2014-12-03       Impact factor: 17.440

4.  Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.

Authors:  A García-de-Lorenzo; S Luque; S Grau; A Agrifoglio; L Cachafeiro; E Herrero; M J Asensio; S M Sánchez; J A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

5.  Penetration of micafungin into the burn eschar in patients with severe burns.

Authors:  Junichi Sasaki; Satoshi Yamanouchi; Yukio Sato; Shinya Abe; Yotaro Shinozawa; Satoshi Kishino; Naoki Aikawa; Shingo Hori
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-06-15       Impact factor: 2.441

Review 6.  Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.

Authors:  Roeland E Wasmann; Eline W Muilwijk; David M Burger; Paul E Verweij; Catherijne A Knibbe; Roger J Brüggemann
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

7.  Penetration of echinocandins into wound secretion of critically ill patients.

Authors:  Tiziana Gasperetti; René Welte; Herbert Oberacher; Jana Marx; Ingo Lorenz; Peter Schellongowski; Thomas Staudinger; Karin Burgmann; Philipp Eller; Tobias Santner; Andrea Griesmacher; Hartwig Pfisterer; Stephan Eschertzhuber; Maria Aigner; Michael Joannidis; Romuald Bellmann
Journal:  Infection       Date:  2021-04-20       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.